Latest Biotechnology News

Page 1 of 115
The US FDA has refused to lift the clinical hold on Argenica Therapeutics’ xaranetide stroke program, demanding a GLP rat neurotoxicity study and imposing a lower exposure limit than the company proposed for Phase 2b. Argenica plans to challenge parts of the assessment while pursuing regulatory submissions elsewhere.
Ada Torres
Ada Torres
19 Nov 2026
An independent interim analysis has confirmed statistically significant iPPS benefits in Paradigm’s rest-of-world knee osteoarthritis cohort, giving the company a possible route to continue development despite the overall trial failing its futility test. Any new trial remains subject to funding, creditor approval and regulatory discussions.
Ada Torres
Ada Torres
19 Nov 2026
Clarity Pharmaceuticals has completed final follow-up assessments for every participant in its registrational Phase III AMPLIFY trial of 64Cu-SAR-bisPSMA. Topline results from AMPLIFY and the related CLARIFY trial are expected in the first half of 2027, with the data intended to support US FDA applications.
Victor Sage
Victor Sage
19 Nov 2026
Actinogen Medical’s pivotal XanaMIA trial produced a mixed result: Xanamem showed a small, non-significant benefit across the full 247-patient population, but a prespecified older-patient analysis found a statistically significant difference in disease stabilisation. The company will continue its open-label extension, suspend future Phase 3 spending and seek development partners.
Victor Sage
Victor Sage
19 Nov 2026
IDT Australia expects FY27 revenue of $19 million to $20 million and EBITDA of $1 million to $1.5 million, marking a projected swing from a $0.92 million FY26 loss. The forecast rests on larger customer contracts, a five-year radiopharmaceutical deal and roughly $7 million of manufacturing upgrades.
Victor Sage
Victor Sage
18 Nov 2026
Racura Oncology has cleared a key ethics hurdle for its pivotal EMILI trial of RC220 in relapsed or refractory acute myeloid leukaemia. The Phase 2b program is funded from existing cash, but efficacy, regulatory and funding tests still stand between the company and Phase 3.
Ada Torres
Ada Torres
18 Nov 2026
Actinogen Medical’s shares have been suspended while it completes analysis of additional data from its pivotal XanaMIA Alzheimer’s trial. The company expects trading to resume no later than 19 November unless the results announcement comes first.
Ada Torres
Ada Torres
17 Nov 2026
Island Pharmaceuticals is moving Galidesivir into a decisive sequence of Marburg animal studies after the FDA confirmed an Animal Rule pathway for the antiviral. The company also expects to generate prospective human data through an approved Uganda Ebola program, although approval, funding and commercial outcomes remain unresolved.
Victor Sage
Victor Sage
17 Nov 2026
AdAlta has taken ownership of the US FDA Orphan Drug Designation for EW-001, strengthening the commercial case for its mesothelioma CAR-T therapy. The designation follows a constructive pre-IND meeting, but approval and clinical success remain unproven.
Ada Torres
Ada Torres
17 Nov 2026
Neurizon has opened a non-underwritten A$2 million share purchase plan at A$0.068 a share, giving eligible shareholders access to the same terms as its recent placement. Participants may also receive one free option for each new share, subject to shareholder approval and ASX quotation conditions, as the company funds its NUZ-001 ALS program towards a late Q2 2027 readout.
Ada Torres
Ada Torres
16 Nov 2026
Vectus Biosystems has received supportive written FDA feedback on VB0004, reducing uncertainty around the drug candidate’s manufacturing, nonclinical and planned clinical development package. The company will now incorporate the guidance into an IND application for a Phase Ib/IIa study in IPF patients in Australia.
Ada Torres
Ada Torres
16 Nov 2026
Moderna’s chief legal officer will retire in March under an agreement that provides US$1.63 million in fixed severance and up to US$8 million linked to litigation outcomes. The package also preserves her salary, benefits and equity vesting through her departure date.
Ada Torres
Ada Torres
14 Nov 2026

Browse the archive

Full archive